| Literature DB >> 22018048 |
David Andaluz-Ojeda1, Verónica Iglesias, Felipe Bobillo, Raquel Almansa, Lucía Rico, Francisco Gandía, Ana Ma Loma, Concepción Nieto, Rosa Diego, Epifanio Ramos, Mercedes Nocito, Salvador Resino, Jose M Eiros, Eduardo Tamayo, Raul Ortiz de Lejarazu, Jesús F Bermejo-Martin.
Abstract
INTRODUCTION: Host immunity should play a principal role in determining both the outcome and recovery of patients with sepsis that originated from a microbial infection. Quantification of the levels of key elements of the immune response could have a prognostic value in this disease.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22018048 PMCID: PMC3334794 DOI: 10.1186/cc10501
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Demographics and clinical characteristics of the patients based upon ICU mortality
| Demographic and clinical characteristics | Survivors | Nonsurvivors | Total population | Survivors vs nonsurvivors |
|---|---|---|---|---|
| Age (years) | 66.0 (20.0) | 72.0 (14) | 68.5 (19.2) | 0.048 |
| Males | 18 (62%) | 14 (66.6%) | 32 (64%) | n.s. |
| APACHE II score at ICU admission | 18.0 (15.0) | 23.0 (10.0) | 20.5 (13.2) | n.s. |
| SOFA score at ICU admission | 7.0 (6.0) | 9.0 (2.0) | 8.0 (4.0) | n.s. |
| Comorbidities | ||||
| Cardiovascular disease | 8 (26.6%) | 7 (35%) | 15 (30%) | n.s. |
| COPD | 2 (6.6%) | 6 (30%) | 8 (16%) | 0.025 |
| Chronic renal failure or dialysis | 2 (6.6%) | 2 (10%) | 4 (8%) | n.s. |
| Diabetes mellitus types 1 and 2 | 10 (33.3%) | 7 (35%) | 17 (34%) | n.s. |
| Alcohol abuse | 2 (6.6%) | 1 (5%) | 3 (6%) | n.s. |
| Hypertension | 12 (41.3%) | 7 (33.3%) | 19 (38%) | n.s. |
| Neoplasia | 3 (10%) | 5 (25%) | 8 (16%) | n.s. |
| Obesity | 2 (6.6%) | 1 (5%) | 3 (6%) | n.s. |
| Diagnostic at ICU admission | ||||
| Severe sepsis | 11 (36.6%) | 1 (5%) | 12 (24%) | 0.007 |
| Septic shock | 18 (62%) | 20 (95.2%) | 38 (76%) | 0.007 |
| Presumed source of infection | ||||
| Lower respiratory tract/pneumonia | 14 (46.6%) | 9 (45%) | 23 (46%) | n.s. |
| Urogenital | 6 (20%) | 3 (15%) | 9 (18%) | n.s. |
| Intra-abdominal | 2 (6.6%) | 3 (15%) | 5 (10%) | n.s. |
| Catheter- or device-related | 1 (3.3%) | 1 (5%) | 2 (4%) | n.s. |
| Skin (soft tissues) | 2 (6.6%) | 1 (5%) | 3 (6%) | n.s. |
| Prosthesis | 2 (6.6%) | 0 (0%) | 2 (4%) | n.s. |
| Central nervous system | 1 (3.3%) | 0 (0%) | 1 (2%) | n.s. |
| Other/unknown | 2 (6.8%) | 4 (19%) | 6 (12%) | n.s. |
| Documented microbial agent | ||||
| Gram-positive | 8 (26%) | 6 (30%) | 14 (28%) | n.s. |
| Gram-negative | 10 (34.4%) | 9 (42.8%) | 19 (38%) | n.s. |
| Fungi | 2 (6.6%) | 1(5%) | 3 (6%) | n.s. |
Continuous variables are expressed as medians (IQR). All other data are raw numbers (%). Proportions were compared using the Χ2 test or Fisher's exact test where appropriate. APACHE II: Acute Physiology and Chronic Health Evaluation II; COPD: chronic obstructive pulmonary disease; SOFA: sequential organ failure assessment score; n.s. = not significant.
Comparison of immunological parameters based upon ICU mortality
| ICU mortality from day 1 | ICU mortality from day 3 | ICU mortality from day 10 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Immunological parameters | Survivors | Nonsurvivors | Survivors | Nonsurvivors | Survivors | Nonsurvivors |
| ||
| IgG (mg/dl) | 844.0 (447.5) | 616.0 (442.5) | 0.035 | 932.0 (371.0) | 685.0 (538.0) | 0.007 | 1,080.0 (602.2) | 764.0 (1068.0) | n.s. |
| IgA (mg/dl) | 240.0 (128.0) | 184.0 (167.0) | n.s. | 280.0 (144.0) | 240.0 (209.0) | n.s. | 334.0 (164.0) | 257.0 (580.8) | n.s. |
| IgM (mg/dl) | 53.0 (47.0) | 60.0 (53.0) | n.s. | 70.0 (85.0) | 67.0 (61.0) | n.s. | 79.5 (66.5) | 42.0 (86.0) | n.s. |
| C3 (mg/dl) | 101.5 (52.3) | 79.0 (60.5) | n.s. | 108.0 (55.0) | 110.0 (89.0) | n.s. | 135.0 (49.0) | 106.0 (81.0) | n.s. |
| C4 (mg/dl) | 24.0 (19.0) | 17.0 (16.0) | 0.029 | 24.0 (16.5) | 28.0 (22.0) | n.s. | 32.0 (18.0) | 20.0 (10.0) | n.s. |
| CD3+ T (cells/mm3) | 417.0 (706.5) | 419.0 (585.0) | n.s. | 639.5 (636.3) | 472.0 (415.0) | n.s. | 774.0 (463.5) | 561.0 (552.0) | n.s. |
| CD4+ T (cells/mm3) | 288.0 (474.5) | 198.0 (400.0) | n.s. | 372.5 (525.8) | 366.0 (423.0) | n.s. | 519.0 (339.0) | 347.0 (355.0) | n.s. |
| CD8+ T (cells/mm3) | 114.0 (258.0) | 156.0 (231.0) | n.s. | 249.5 (199.0) | 120.0 (145.0) | n.s. | 287.0 (296.0) | 204.0 (314.0) | n.s. |
| CD4+ CD8+ T (cells/mm3) | 5.0 (12.0) | 6.0 (13.5) | n.s. | 5.0 (9.0) | 6.5 (24.0) | n.s. | 12.0 (18.3) | 6.0 (54.0) | n.s. |
| LB (cells/mm3) | 103.0 (165.5) | 184.0 (281.0) | n.s. | 163.0 (125.0) | 127.0 (168.0) | n.s. | 118.0 (151.0) | 92.0 (131.0) | n.s. |
| NK (cells/mm3) | 56.8 (59.5) | 98.0 (392.0) | 0.050 | 59.5 (72.5) | 42.0 (73.0) | n.s. | 86.0 (78.0) | 92.0 (38.0) | n.s. |
Data are expressed as medians (IQR). n.s. = not significant. Normal values in adult healthy individuals are as follows: immunoglobulin G (IgG) = 870 to 2,180 mg/dl, IgA = 117 to 420 mg/dl; IgM = 60 to 220 mg/dl; CD3+ T cells = 690 to 2,540 cells/mm3; CD4+ T cells = 410 to 1,590 cells/mm3; CD8+ T cells = 190 to 1,140 cells/mm3; CD4+ CD8+ T cells = not available; B lymphocytes (LB) = 90 to 660 cells/mm3; natural killer (NK) cells = 90 to 590 cells/mm3; complement factor 3 (C3) = 50 to 120 mg/dl; complement factor 4 (C4) = 14 to 70 mg/dl.
Figure 1Kaplan-Meier curves. Deciles from percentile 10 to percentile 90 of natural killer (NK) cell counts measured at day 1 were calculated and used to compare survival times in those patients with low or high concentrations of NK cells in their blood. The first decile shows significant differences between groups based upon the log-rank test (Mantel-Haenzel) and was used as the cutoff (percentile 60 (83 cells/mm3)). Outcome for this analysis was time until death. Time was censored at day 28. Cum Surv: cumulative survivors; NK: natural killer.